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Comparison of Trimethoprim-Sulfamethoxazole with Ampicillin in Acute Infectious
Exacerbations of Chronic Bronchitis: A Double-Blind Crossover Study
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Boston University School of Medicine, Boston,
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Two separate acute bacterial exacerbations of chronic bronchitis or chronic asthmatic
bronchitis were treated in 20 patients in a double-blind crossover study. One course of
treatment consisted of 320 mg of trimethoprim (TMP) plus 1,600 mg of sulfamethox-
azole (SMZ) daily and the other of 2 g of ampicillin daily; each drug was given for 14
days. Patients were observed initially, twice a week during therapy, and weekly after
therapy. Observations that were recorded included graded chest symptoms and physical
findings, vital signs, pulmonary function, hematologic parameters, and objective
sputum measurements (daily volume, purulence, differential quantitative cytology,
quantitative bacterial counts, physical properties, levels of lactate dehydrogenase with
its isoenzymes, levels of myeloperoxidase, and presence of deoxyribonucleic acid
fibers). Both antibiotic regimens were effective in resolving these acute bacterial exacer-
bations. Paired z-test analysis revealed few and minor differences between TMP-SMZ
and ampicillin during therapy, although three patients did not complete TMP-SMZ
therapy because of adverse reactions. However, the period between the two bacterial ex-
acerbations was significantly longer after ampicillin therapy. Innovative in this in-
vestigation are the study design and the objective quantitative measurements of inflam-
matory response and bacterial populations in sputum.
Acute bacterial bronchitic exacerbations are im-
portant clinical events in chronic bronchitis
because of their contribution to morbidity.
Although Koch's postulates are difficult to prove
in this setting, the overwhelming conclusion based
on experience is that treatment with antibiotics is
temporally related to clinical recovery. Many an-
timicrobial agents appear to be effective in treat-
ment of these acute bacterial exacerbations, and
trimethoprim-sulfamethoxazole (TMP-SMZ) is
among the more recent additions to this list. Like
most of these antibiotics, TMP-SMZ has been ex-
perimentally demonstrated to be effective in acute
bacterial bronchitic exacerbations by means of a
limited number of objective measurements in ran-
domly assigned, parallel investigations. To a large
extent, the objective criteria of sputum volume,
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gross sputum purulence, bacterial culture,
pulmonary function, and vital signs are only in-
direct measures of the infectious process. As such,
they lack the preciseness needed for the determina-
tion of possible differences between alternative
methods of therapy.
Methods developed by Chodosh and colleagues
have been used to compare the efficacy of various
types of antimicrobial therapy in acute bac-
terial exacerbations of chronic bronchitis. Some
of the measurements provide criteria that more
closely reflect the level of bronchopulmonary in-
flammation and the size of bacterial populations.
In this study, these criteria were employed to com-
pare the efficacy and safety of TMP-SMZ with the
efficacy and safety of ampicillin in the treatment
of acute bacterial exacerbations in patients with
chronic bronchitis. The crossover design utilized
in this double-blind study ensured that the two
groups of patients treated were entirely similar.
Materials and Methods
Selection of patients. Adult outpatients with
518
chronic bronchitis who developed an acute bron-
chial infectious exacerbation within two weeks of
the initial visit to the clinic were volunteers for this
study. Chronic bronchitis, chronic bronchial
asthma, and emphysema were diagnosed by use of
at least the minimal standards of the American
Thoracic Society [1]. All patients were monitored
in the clinic. Acute bronchial infectious exacerba-
tions were defined by use of clinical and labora-
tory criteria. Clinical manifestations included in-
creases in chest congestion, cough, and volume of
sputum; changes in gross characteristics of
sputum; dyspnea; fever; and chills. Detection of
new pulmonary infiltrate on chest X ray excluded
any patient from the study. On a patient's initial
visit, the cellular composition and bacterial flora
of the sputum were determined by use of a wet
preparation [2] and a gram stain. The finding of
>S 070 polymorphonuclear eosinophils or swollen
bronchial epithelial cells with inclusion bodies ex-
cluded the patient from the study. The absence of
an increase of bacteria morphologically resem-
bling Haemophilus influenzae or Streptococcus
pneumoniae or the predominance of organisms
suggestive of Pseudomonas, Klebsiella, or
Staphylococcus species also excluded the patient
from the study. Only patients who had not re-
ceived an antibiotic in the week before the initial
visit, who were able to return for the required
visits, and who gave their informed consent to be
in the experiment were included. Patients who
could not complete either of the two courses of
therapy were excluded from the analysis.
Design of the study. Patients with the pre-
requisite criteria were assigned to one of two treat-
ment programs by random selection. Patients
were automatically assigned to the other of the
two treatment programs if a second infectious
exacerbation occurred. The randomization code
was unknown to the investigators, patients, and
technicians. Placebo capsules and tablets were
concomitantly administered so that each dose was
entirely similar for each couse of therapy. Both
drugs were administered for 14 days. The dosage
schedule for ampicillin was one SOO-mg capsule
four times a day; for TMP-SMZ it was two tablets
twice a day, with each tablet containing 80 mag of
TMP and 400 mg of SMZ. During each infectious
exacerbation, the patient was seen initially (before
therapy); at days 3, 7, 10, and 14 (all ±1) during
Chodosh et 01.
therapy; and at days 7 and 14 after therapy. All
other ancillary therapy was continued as regularly
as was clinically feasible. Each patient was ob-
served by a single investigator.
Observations. Clinical observations and stud-
ies of sputum and pulmonary function were made
at each visit. These observations included oral
temperature, pulse rate, and respiratory rate. The
history of the acute infectious exacerbation was
recorded at the initial visit, and the subjective
pulmonary symptoms were recorded at each visit
by use of a graded system. Frequency of cough in
the morning, daytime, evening, and nighttime was
reported and assigned a value of 0-20, with 0 sig-
nifying no cough, 20 signifying almost continuous
cough, and 7 signifying one cough per hour. The
average severity of cough was rated 1-20, with 7
representing easily perceptible cough not interfer-
ing with activities, IS representing dizziness with
cough, and 20 representing cough syncope. Dys-
pnea was rated 0-20, with 9 signifying shortness of
breath after two flights of stairs and 20 represent-
ing shortness of breath at rest. (The scales were
subdivided between these given examples.)
The chest examination was limited to six
anterior and six posterior areas. Adventitious
sounds, intensity of breath sounds, and prolonga-
tion of the expiratory phase were recorded with a
graded system in which 0 represented a normal
finding and 20 the most extreme finding. For each
of the adventitious sounds (rales, rhonchi, and
wheezes), the sum of the grades on both inspira-
tion and expiration for the 12 auscultated areas
was recorded, with a maximal possible score of
480.
The patient's impression of the course of the at-
tack was noted for the interval between each pair
of visits. The scale ranged from - 7 (very much
worse) to 0 (no change) to + 7 (very much better),
with intermediate changes graded between. The
cumulative score over time was used in analysis.
The sputum observations were made with a col-
lection of all material coughed up from deep in the
chest during the 24 hr before each visit. After the
volume of this material for the 24-hr period was
recorded, aliquots were sampled by the method of
Chodosh et al. [3]. Only representative material
that was seen by microscopy to be of bronchopul-
monary origin was used for all subsequent obser-
vations. The color of the sputum was graded, with
TMP-SMZ vs. Ampicillin in Bronchitis
oequal to clear, 4 equal to yellow, and 6 equal to
green. One aliquot was used for cytologic and
gram-stain preparations, a second for biochemical
assays, and a third for bacteriologic cultures. The
cytologic characteristics of the 24-hr sputum
volume were determined qualitatively and quan-
titatively. The cell concentration was determined
by counting in a hemocytometer, and the percen-
tage of each cell type was differentially counted in
Papanicolaou-stained sputum smears, as described
by Medici and Chodosh [4]. From these values,
the numbers of polymorphonuclear neutrophils,
bronchial epithelial cells, histiocytes, and
eosinophils excreted per day were calculated.
Other types of cells were also differentiated, but
the data will not be reported here. Average
histiocyte size was determined from measurements
of at least 50 consecutive cells in mounts of fresh,
unfixed sputum.
Levels of L( + )-lactate dehydrogenase (LDH)
were measured in duplicate assays with the model
DU Beckman spectrophotometer (Beckman In-
struments, Fullerton, Calif.) with sodium
pyruvate and reduced nicotinamide adenine
dinucleotide (NADH) at a pH of 7.4 [5]. The
values were reported as umoles of NADH ox-
idized/ml of homogenized sputum per min. Levels
of isoenzymes of LDH were determined by paper
electrophoresis [6]. Levels of myeloperoxidase were
determined by a new spectrophotometric method
that uses NADH 2 and the diorthoquinone-type
polyphenol nordihydroguaiaretic acid in 0.05 M
phosphate buffer at pH 7.0 and followed at 340
11m (B. Eichel, unpublished observations). DNA
fibers were assayed histochemically by fluorescent
microscopic examination of acridine orange-
stained smears; the relative amount of these fibers
was graded on a scale of 0 to 4 [6].
Bacteriologic studies included gram staining
and colony counts of specific organisms. From the
gram-stained preparations, the average numbers of
each morphologic bacterial type per uniform oil-
immersion field were determined for 20 adequate
oil-immersion fields, as described by Chodosh and
Medici [7]. An adequate field was defined as one
with at least three cells originating from the bron-
chopulmonary system but no more such cells than
would constitute a single cell layer . Although col-
ony counts were made, the results will not be
reported here.
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The physical properties of apparent viscosity
and adhesiveness were measured by the Chodosh
inclined-tube method [8], in which the time-
distance relations are measured as the sputum
descends the 8° incline. The apparent viscosity
factor reflects the internal forces that are keeping
the sputum from stretching and is the product of
the square of 10 times the slope of the first slow
phase times the log of the time of the intercept of
this slope at zero distance. The adhesiveness
reflects the sticking of the sputum to the tube and
is measured as the log of the time (in seconds) re-
quired for the sputum to move the first 2 mm
down the tube.
The pulmonary function tests at each visit in-
cluded determination of the forced expiratory
flow between 200 and 1,200 ern! of the forced vital
capacity, the forced expiratory volume in 1 sec,
the forced vital capacity, and the slow vital capaci-
ty. A pulmonary function recorder spirometer
(Airshields, Hatboro, Pa.) was used in these tests.
Statistical analysis. The mean, SD, and SE
values for each observation at each visit were
calculated. Comparisons between the value before
therapy and all subsequent values and between
values for the two drugs at each observation time
were made by means of paired r-tests, Probability
values of ~0.05 were considered to be statistically
significant. In the statistical tests, log transforma-
tions were used for the measurement of cells ex-
creted per day and gram-stain quantitation. The
Wilcoxon signed-rank test was used for analysis of
the duration of the infection-free period after
therapy.
Results
Twenty-one patients received both ampicillin and
TMP-SMZ for a total of 42 separate acute infec-
tious exacerbations of bronchitis. One patient had
an anaphylactic-like reaction after the first dose of
TMP-SMZ; when data for this patient were ex-
cluded, 20 pairs of exacerbations remained for use
in our analysis. Twelve patients were men and
eight were women, with a mean age of 53 years
and an age range of 30-78 years. Eighteen of the
patients had chronic bronchitis, and two had
chronic asthmatic bronchitis; seven patients had
associated chronic pulmonary emphysema, and
five of the patients with chronic bronchitis also had
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chronic bronchial asthma. Eight patients received
ampicillin first, and twelve started with TMP-
SMZ. For 17 patients the median interval before
the next bacterial exacerbation could be determin-
ed after treatment with both agents; this interval
was 96 days after ampicillin therapy and 62 days
after TMP-SMZ therapy. For 13 of these 17 pa-
tients, the infection-free period was longer after
ampicillin therapy than after TMP-SMZ therapy
(0.05 > P> 0.02).
The mean and SE values for graded symptoms
and physical findings are shown in table 1. The
cumulative ratings for changes in the course of
recovery from the attack reflected significant im-
provement between each visit during treatment,
regardless of which drug was being used. How-
ever, these values were not significantly different
for the two drugs. Compared with values before
therapy, the frequency of morning cough was sig-
nificantly reduced starting on day 7 during treat-
ment with either drug; the severity of morning
cough was significantly reduced on days 3-21 with
TMP-SMZ therapy and on days 7-28 with ampi-
cillin therapy. Dyspnea was significantly reduced
only on day 28 with ampicillin therapy. The severi-
ty of wheezing was significantly reduced on days
7-21 with TMP-SMZ therapy but only on day 28
with ampicillin therapy. Sputum thickness was
significantly reduced beginning on day 7 of
therapy with either agent. Vital signs did not
change significantly during either type of therapy.
Although all adventitious respiratory sounds de-
creased during therapy, no decrease was signifi-
cant. The only statistically significant difference
between drugs occurred on day 21, when the sever-
ity of morning cough was reduced to a greater ex-
tent in patients who had taken ampicillin. Adven-
titious sounds increased (although not significant-
ly) after TMP-SMZ therapy was completed.
Table 1 also shows the results of pulmonary
function tests. Although these values increased
during ampicillin therapy, the changes were not
statistically significant.
Table 2 shows the mean and SE values for find-
ings in sputum: daily volume, gross appearance,
specific cells excreted per day, and numbers of
specific morphologic types of bacteria per oil-im-
mersion field. Compared with values before ther-
apy, sputum volume was decreased significantly at
all observation times starting with day 3 of treat-
ment with either drug. The percentage of sputum
that appeared purulent was significantly reduced
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at the same observation times with ampicillin
therapy but only on day 14 with TMP-SMZ
therapy. The sputum color became significantly
clearer starting on day 3 of therapy with either an-
tibiotic. The number of polymorphonuclear
neutrophils excreted in the sputum per day (an
estimate of the inflammatory level) decreased
significantly starting on day 3 of either type of
therapy. The number of histiocytes excreted in the
sputum per day (an estimate of host cellular
response) did not change significantly, while the
average size of histiocytes significantly increased
on days 7 and 14 of TMP-SMZ therapy. The
number of bronchial epithelial cells excreted in the
sputum per day (a measure of mucosal damage)
decreased significantly starting on day 3 of TMP-
SMZ therapy and on day 10 of ampicillin therapy;
bronchial epithelial cells with intracellular bacteria
(an indicator of the level of mucosal infection)
decreased significantly in number by day 10 of
ampicillin therapy and by day 14 of TMP-SMZ
therapy and remained reduced. The number of
eosinophils excreted in the sputum per day in-
creased significantly on day 10 of TMP-SMZ
therapy. The number of Haemophilus-like
microorganisms was significantly reduced on days
3-28 with ampicillin therapy and on day 3 and
days 10-21 with TMP-SMZ therapy. The number
of gram-positive pneumococci was significantly
reduced on days 3-14 of either type of therapy and
on day 28 with ampicillin therapy. Diphtheroid-
like microorganisms were significantly reduced in
numbers on days 3-14 of ampicillin therapy and
on days 7 and 10 of TMP-SMZ therapy. Numbers
of Neisseria-like microorganisms were significant-
ly reduced on days 3-14 of TMP-SMZ therapy but
not with ampicillin therapy. The few isolated dif-
ferences between drugs did not reflect a persistent
trend.
Table 3 shows changes in some biochemical
constituents and physical properties of sputum
and in peripheral blood. LDH activity of sputum
was significantly reduced on days 7-28 with am-
picillin therapy and on days 7-14 of TMP-SMZ
therapy. The isoenzymes of LDH showed a
variable pattern; for example, the activity of
isoenzyme 3 was reduced with either drug (on days
7, 10, 21, and 28 with TMP-SMZ therapy and on
day 21 with ampicillin therapy), whereas that of
isoenzyme 5 did not change significantly with
either type of treatment. Myloperoxidase activity
in sputum decreased during recovery in the same
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TMP-SMZ vs. Ampicillin in Bronchitis
pattern as was noted for LDH. Values for DNA
fibers in sputum were decreased during and after
therapy, but not significantly. Physical properties
of sputum, measured by the inclined tube method,
did not change significantly except for a decrease
in adhesiveness on day 28 with ampicillin therapy.
The white blood cell count in peripheral blood
decreased significantly on days 7-21 with TMP-
SMZ therapy and on day 7 and days 14-28 with
ampicillin therapy, although all of the mean
values were within the normal range. The platelet
count decreased significantly on day 3 and days
10-28 with ampicillin therapy and on days 14 and
21 with TMP-SMZ therapy. Levels of hemoglobin
decreased significantly only on day 21 with TMP-
SMZ therapy.
Table 4 lists the adverse reactions described as
probably or possibly related to TMP-SMZ and
ampicillin. Diarrhea was more commonly noted
during therapy with ampicillin. All 21 patients
completed the prescribed course of ampicillin, but
three patients discontinued TMP-SMZ therapy
because of adverse reactions. One patient stopped
taking TMP-SMZ after a single dose because of an
anaphylactic-like reaction, a second because of a
painful cracked tongue, and a third because of
nausea and vomiting. The number of patients with
adverse reactions and the number of reactions
were otherwise similar for the two drugs.
Discussion
This investigation confirmed the efficacy of
TMP-SMZ, as noted by other investigators, in the
treatment of acute bacterial exacerbations of
chronic bronchitis. However, the expectation,
based on our earlier report [9], that TMP-SMZ
might be more efficacious than ampicillin was not
realized. Various ratios of TMP and SMZ
employed by other investigators have been found
to be comparable or superior to other commonly
used antibiotics for the treatment of acute
bacterial bronchitic exacerbations. Drew et al. [10]
used a total daily dose of 500 mg of TMP plus
1,000 mg of SMZ for cases in which other types of
treatment had failed; the results were uniformly
successful. In another study, Barn and co-workers
[11] obtained comparable results with total daily
doses of either 160 mg of TMP plus 800 mg of
SMZ or 600 mg of methacycline. Other in-
vestigators [12-14] used 320 mg of TMP plus
1,600 mg of SMZ daily and compared the results
523
with those of either ampicillin or tetracycline
therapy. In general, this dosage of TMP-SMZ was
more effective than the other agents. Pines [15]
further demonstrated that 480 mg of TMP plus
2,400 mg of SMZ was significantly more effective
than tetracycline. Investigations by Hughes et al.
[16] and Pines et al. [17] of different dosages of
TMP-SMZ indicate that a total daily dosage of
either 500 mg of TMP plus 1,000 mg of SMZ or 480
mg of TMP plus 2,400 mg of SMZ was more ef-
fective than the dosage of 320 mg of TMP plus
1,600 mg of SMZ used in the present investiga-
tion; however, the latter dosage was more effec-
tive than a dosage of 200 mg of TMP plus 2,000
mg of SMZ. It would appear from these data that
the dose of TMP is related to the degree of ef-
ficacy of treatment.
The results of the present investigation support
the comparability of effectiveness of TMP-SMZ
and that of ampicillin during the active treatment
period. However, changes during the observation
period after therapy suggested that the effects of
accepted dosages of TMP-SMZ are not as persis-
tent as those of ampicillin. Although these
changes were not significant compared with
baseline values, increases of cough severity, rales,
rhonchi, wheezing, and bacterial numbers were
noted 14 days after discontinuation of TMP-SMZ
therapy. Since the majority of the patients in this
study had new bacterial exacerbations sooner after
TMP-SMZ therapy than after ampicillin therapy,
it is possible that these changes in the two weeks
after therapy had some predictive value.
A number of important factors influence the
choice of therapy for acute exacerbations of
chronic bronchitis. First, the probable etiology of
the exacerbation must be ascertained. If the
etiology is bacterial, the next consideration is the
selection of the antimicrobial agent most likely to
elicit a prompt response and to exert a sustained
suppressive effect that will prolong the infection-
free period. Other considerations relate to com-
pliance of the patient with the regimen. The level
of toxicity of the drug should be low, and the
dosage schedule should be conducive to com-
pliance. The overall goal is to reduce morbidity
among these chronically ill patients. The design of
investigations of the efficacy of antimicrobial
agents in acute bacterial exacerbations of chronic
bronchitis should promote as objective an assess-
ment of these factors as possible.
Judgments about the efficacy of antibacterial
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Table 4. Adverse reactions noted during treatment of
acute bacterial exacerbations of chronic bronchitis in 21
patients with trimethoprim-sulfamethoxazole (TMP-
SMZ) or ampicillin.
* Each patient experienced at least two acute bacterial bron-
chitic exacerbations, one of which was treated with TMP-SMZ
and the other with ampicillin. A total of 12 patients had one or
more adverse reactions to TMP-SMZ, and 13 patients had such
reactions to ampicillin. Three patients discontinued treatment
with TMP-SMZ because of adverse reactions.
level of the lung, such as the purulence, levels of
LDH, and presence of DNA in the sputum. These
determinations may be correlated with the degree
of inflammation, but because they are not very
specific an additional source of error in the selec-
tion of subjects is introduced.
These basic prerequisites for inclusion in an
evaluation of antimicrobial efficacy have been
adhered to in the present investigation. With ef-
fective antibacterial therapy, these objective find-
ings, as well as the subjective symptoms, should
improve. A decrease of the bacterial numbers seen
in gram-stained preparations should precede the
decrease of sputum inflammatory level, and this
decrease in the bacterial population should persist
after therapy is discontinued. The subjective
No. of patients with reaction
to indicated regimen"
3
1
1
5
2
1
1
1
o
1
1
1
8
o
o
o
o
1
27
Ampicillin
4
2
1
5
4
2
o
o
2
1
1
2
1
o
o
1
o
27
TMP-SMZ
Painful, cracked, or
burning tongue
Sore mouth
Dry lips
Nausea
Vomiting
Epigastric pain or
heartburn
Anorexia
Eructation
Diarrhea or loose stools
Constipati on
Abdominal pain
Flatulence
Bronchospasm
(anaphylactic-like)
Photophobia or
painful eyes
Vaginitis
Weakness
Nervousness
Exacerbation of gouty
arthritis
Total
Reaction
agents should be made only on the basis of results
with patients who clearly have acute bacterial ex-
acerbations of chronic bronchitis. The common
clinical practice of presumptively diagnosing
bacterial infection based on acute worsening of
chest symptoms is an insufficiently precise means
of selecting appropriate subjects for investiga-
tions. The symptoms of increased cough, chest
congestion, change of sputum color to yellow or
green, increased dyspnea, feverishness, and
malaise are not specific to bacterial infection.
Nonbacterial infection, allergy, and secretion
clearance problems are frequently the basis for
this clinical syndrome. The diagnosis of bacterial
infection should be based on objective evidence of
increased bacterial flora and increased inflam-
matory level [18, 19]. These conditions are best
determined by direct observation of the sputum.
The criterion for increased bacterial flora is the
observation of at least 8, 15, or 25 pneumococcus-
like, Haemophilus-like, or mixed organisms,
respectively, per oil-immersion field in a gram-
stained preparation of sputum. Most investigators
have depended on the recovery of potential
pathogens from cultures for estimation of the
bacterial flora, but in our studies this criterion has
been less specific than gram-stain criteria. Even
careful quantitative colony counts of each
bacterial type are only poorly correlated with both
the clinical course and the gram-stain observa-
tions. Pathogens from the resident flora in the
bronchi or the oropharynx are frequently
recovered from the sputum of patients with
chronic bronchitis, even when their condition is
stable.
The level of inflammation in the bronchial tree
can be directly assessed by a determination of the
number of polymorphonuclear neutrophils ex-
creted in the sputum per day. This value is depen-
dent on the volume of exudate and secretions pro-
duced by the lung, on the concentration of cells in
this sputum, and on the percentage of these cells
that are neutrophils. Investigators who depend on
only one or two of these determinants of the
inflammatory level are accepting an undesirably
high margin of error in the selection of appropri-
ate subjects. Also, unless the level of inflamma-
tion before infection has been documented, any
change becomes a matter of subjective interpreta-
tion. Other investigators have used criteria that in-
directly measure the neutrophilic inflammatory
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symptoms should also return to the stable levels
noted prior to the acute exacerbation.
The methodology developed for objective
measurements in sputum and for the more critical
clinical observations has permitted definitive com-
parison of antibacterial agents in the treatment of
acute bacterial exacerbations of chronic bron-
chitis. The same techniques have been used to
study allergic bronchial inflammation in asthma
[20] as well as in other sputum-producing lung
diseases [21]. Indeed, the sputum produced in a
variety of bronchopulmonary diseases provides an
unusual opportunity to study the myriad aspects
of the inflammatory process virtually in vivo at
the human level. Some of the sputum observations
in this investigation offer insight into the inflam-
matory process during an infectious insult to the
bronchial tree. For example, the extent of the
bacterial infectious process can be assessed by a
determination of the number of exfoliated bron-
chial epithelial cells containing intracellular
bacteria. The decrease during therapy coincides
with clinical and objective improvement.
Although viability of these bacteria cannot be
determined by the methods used in this study,
their presence at the end of therapy lends support
to the observation of Hers [22] that H. influenzae
was recovered from mucosal biopsies at the end of
a course of antibacterial therapy. The persistence
of bacteria in the bronchial mucosa is consistent
with the assumption that available antibacterial
agents are capable of reducing but not eliminating
the bacterial load in the lung tissue. The recur-
rence of acute bacterial infections in the patients
in this study may well be attributable to this resi-
dent population of bacteria, but the evidence does
not exclude the etiologic importance of newly in-
haled bacteria.
The changes in the number of bronchial
histiocytes provide a measure of how closely the
acute inflammatory process is actually paralleling
the expected progression. The expected increase in
the number of macrophages as the number of
neutrophils decreases during recovery was not
demonstrated in this group of patients. However,
the size of bronchial histiocytes did increase dur-
ing recovery from the bronchial infection. This
observation is consistent with the entry of small
macrophages into the bronchial exudate during
Chodosh et at.
active infection - probably as blood monocytes
whose protoplasmic mass increases with their
phagocytic activity.
LDH activity in sputum has been used by other
investigators as a measure of inflammation [6].
The decrease of LDH activity noted during
recovery is consistent with the observations of
these investigators, but the difference in the
responses of the various LDH isoenzymes appears
to be a new finding. Although the total activity of
LDH decreases with recovery, the percentage of
LDH isoenzyme 5 remains consistent throughout
the course of the attack, while the percentage of
isoenzyme 3 decreases. The cellular source of these
isoenzymes in sputum and the basis for this dif-
ference are not known. The relative distribution of
the isoenzymes in sputum is different from the
pattern observed in blood.
Sputum myeloperoxidase is thought to represent
the peroxidase of polymorphonuclear leukocytes
important in intracellular bacterial killing. In our
patients, myeloperoxidase activity decreased dur-
ing recovery in the same pattern as was noted for
LD H. The decrease was not proportional to the
total number of sputum neutrophils - a fact sug-
gesting that the relation of myeloperoxidase to
polymorphonuclear leukocytes needs to be more
carefully examined.
Other investigators have used the number of
DNA fibers in sputum as an index of inflamma-
tion [6]. As measured by the technique used here,
these fibers reflect the amount of cellular break-
down. The results of the current investigation do
not support the significant decrease in the number
of DNA fibers reported by others, although the
values did decrease with recovery.
Measurement of physical properties of spu-
tum-e.g., apparent viscosity and adhesive-
ness - does not confirm the subjective impression
of patients that their sputum becomes thinner dur-
ing recovery. It is possible that patients relate
other changes in their sputum to thickness or that
the method for measuring these factors in sputum
is inadequate to detect changes [8].
The results of this investigation suggest that the
use of some definitive and some subtle objective
measurements facilitates the comparison of an-
tibacterial drugs in this clinical setting. The use of
each patient as his or her own control also makes
TMP-SMZ vs. Ampicillin in Bronchitis
the assessment more reliable. In addition,
mechanisms of the inflammatory process can be
examined at the human level.
Results of the comparison of TMP-SMZ and
ampicillin in this investigation appear to favor am-
picillin in that the duration of the infection-free
period was longer after ampicillin therapy and the
adverse reactions to TMP-SMZ were more sub-
stantive clinically. The literature suggests that use
of a higher daily dose of TMP-SMZ might have
resulted in a better response to this agent.
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